Lead optimization of [(S)-γ-(arylamino)prolyl]thiazolidine focused on γ-substituent: Indoline compounds as potent DPP-IV inhibitors

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 2, 2007, Pages 641-655

  Sakashita, Hiroshi ^a   Akahoshi, Fumihiko ^a   Yoshida, Tomohiro ^a   Kitajima, Hiroshi ^a   Hayashi, Yoshiharu ^a   Ishii, Shinichi ^a   Takashina, Yoko ^a   Tsutsumiuchi, Reiko ^b   Ono, Satoshi ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b Technology and Production Division   (Japan)

Author keywords

DPP IV inhibitor; Indoline; Thiazolidine

Indexed keywords

3 (1 TERT BUTOXYCARBONYL 4 HYDROXY 2 PYRROLIDINYLCARBONYL) 1,3 THIAZOLIDINE; 3 (4 BENZOYLAMINO 2 PYRROLIDINYLCARBONYL) 1,3 THIAZOLIDINE; 3 (4 BENZOYLOXY 2 PYRROLIDINYLCARBONYL) 1,3 THIAZOLIDINE; 3 (4 BENZYLAMINO 2 PYRROLIDINYLCARBONYL) 1,3 THIAZOLIDINE; 3 (4 PHENYLSULFONYLAMINO 2 PYRROLIDINYLCARBONYL) 1,3 THIAZOLIDINE; 3 [4 (3 PHENYLUREIDO) 2 PYRROLIDINYLCARBONYL] 1,3 THIAZOLIDINE TRIFLUOROACETATE; 3 [4 (4 CYANOBENZOYL)AMINO 2 PYRROLIDINYLCARBONYL] 1,3 THIAZOLIDINE; 3 [4 (4 CYANOBENZOYL)OXY 2 PYRROLIDINYLCARBONYL] 1,3 THIAZOLIDINE; 3 [4 (4 CYANOPHENYLMETHYL)AMINO 2 PYRROLIDINYLCARBONYL] 1,3 THIAZOLIDINE; 3 [4 (4 CYANOPHENYLSULFONYL)AMINO 2 PYRROLIDINYLCARBONYL] 1,3 THIAZOLIDINE; 3 [4 (5 METHOXY 1 INDOLINYL) 2 PYRROLIDINYLCARBONYL] 1,3 THIAZOLIDINE; 3 [4 [3 (4 CYANOPHENYL)UREIDO] 2 PYRROLIDINYLCARBONYL] 1,3 THIAZOLIDINE; 3 [4 [BIS(4 CYANOPHENYLMETHYL)]AMINO 2 PYRROLIDINYLCARBONYL] 1,3 THIAZOLIDINE; 3 [4 [N (4 CYANOBENZOYL) N (4 CYANOPHENYLMETHYL)AMINO] 2 PYRROLIDINYLCARBONYL] 1,3 THIAZOLINE; 3 [4 [N (4 CYANOPHENYLMETHYL) N (2 HYDROXYETHYL)AMINO] 2 PYRROLIDINYLCARBONYL] 1,3 THIAZOLIDINE; 3 [4 [N (4 CYANOPHENYLMETHYL) N (ETHOXYCARBONYLMETHYL)AMINO] 2 PYRROLIDINYLCARBONYL] 1,3 THIAZOLIDINE; 3 [4 [N (4 CYANOPHENYLMETHYL) N ISOPROPYLAMINO] 2 PYRROLIDINYLCARBONYL] 1,3 THIAZOLIDINE; 3 [4 [N (4 CYANOPHENYLMETHYL) N METHYLAMINO] 2 PYRROLIDINYLCARBONYL] 1,3 THIAZOLIDINE; 3 [4 [N (CARBAMOYLMETHYL) N (4 CYANOPHENYLMETHYL)AMINO] 2 PYRROLIDINYLCARBONYL] 1,3 THIAZOLIDINE; 3 [4 [N (CARBOXYMETHYL) N (4 CYANOPHENYLMETHYL)AMINO] 2 PYRROLIDINYLCARBONYL] 1,3 THIAZOLIDINE 2 TRIFLUOROACETATE; 3 [4 [N BUTYL N (4 CYANOPHENYLMETHYL)AMINO] 2 PYRROLIDINYLCARBONYL] 1,3 THIAZOLIDINE; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO] NICOTINONITRILE; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE 8; DIPEPTIDYL PEPTIDASE 9; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INDOLE DERIVATIVE; PROLYLTHIAZOLIDINE DERIVATIVE; THIAZOLIDINE DERIVATIVE; UNINDEXED DRUG;

ARTICLE; DRUG BINDING; DRUG CONFORMATION; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; REACTION OPTIMIZATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIGENS, CD26; BINDING SITES; HUMANS; INDICATORS AND REAGENTS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEASE INHIBITORS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINES;

EID: 33845321976     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.10.059     Document Type: Article

References (21)

1. Heins J., Welker P., Schönlein C., Born I., Hartrodt B., Neubert K., Tsuru D., and Barth A. Biochim. Biophys. Acta 954 (1988) 161
2. Deacon C.F., Johnsen A.H., and Holst J.J. J. Clin. Endocrinol. Metab. 80 (1995) 952
3. Ørskov C. Diabetologia 35 (1992) 701
4. Holst J.J., and Deacon C.F. Diabetes 47 (1998) 1663
5. Lankas G.R., Leiting B., Roy R.S., Eiermann G.J., Beconi M.G., Biftu T., Chan C.C., Edmondson S., Feeney W.P., He H., Ippolito D.E., Kim D., Lyons K.A., Ok H.O., Patel R.A., Petrov A.N., Pryor K.A., Qian X., Reigle L., Woods A., Wu J.K., Zaller D., Zhang X., Zhu L., Weber A.E., and Thornberry N.A. Diabetes 54 (2005) 2988
6. For comprehensive reviews of DPP-IV inhibitors:. Gwaltney II S.L., and Stafford J.A. Annu. Rep. Med. Chem. 40 (2005) 149
7. Weber A.E. J. Med. Chem. 47 (2004) 4135
8. Hughes T.E., Mone M.D., Russell M.E., Weldon S.C., and Villhauer E.B. Biochemistry 38 (1999) 11597
9. Villhauer E.B., Brinkman J.A., Naderi G.B., Dunning B.E., Mangold B.L., Mone M.D., Russell M.E., Weldon S.C., and Hughes T.E. J. Med. Chem. 45 (2002) 2362
10. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., Mangold B.L., Russell M.E., and Hughes T.E. J. Med. Chem. 46 (2003) 2774
11. McIntyre J.A., and Castańer J. Drugs Future 29 (2004) 887
12. Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G., Wang A., Simpkins L.M., Taunk P., Huang Q., Han S.P., Abboa-Offei B., Cap M., Xin L., Tao L., Tozzo E., Welzel G.E., Egan D.M., Marcinkeviciene J., Chang S.Y., Biller S.A., Kirby M.S., Parker R.A., and Hamann L.G. J. Med. Chem. 48 (2005) 5025
13. Sorbera L.A., Revel L., and Castańer J. Drugs Future 26 (2001) 859
14. Pospisilik J.A., Stafford S.G., Demuth H.-U., Brownsey R., Parkhouse W., Finegood D.T., McIntosh C.H.S., and Pederson R.A. Diabetes 51 (2002) 943
15. Sakashita H., Kitajima H., Nakamura M., Akahoshi F., and Hayashi Y. Bioorg. Med. Chem. Lett. 15 (2005) 2441
16. Sakashita H., Akahoshi F., Kitajima H., Tsutsumiuchi R., and Hayashi Y. Bioorg. Med. Chem. 14 (2006) 3662
17. Ashworth D.M., Atrash B., Baker G.R., Baxter A.J., and Jenkins P.D. Bioorg. Med. Chem. Lett. 6 (1996) 1163
18. Villhauer, E. B. US006107317A.
19. Rasmussen H.B., Branner S., Wiberg F.C., and Wagtmann N. Nat. Struct. Biol. 10 (2003) 19
20. Goto, J.; Kataoka, R.; Hirayama, N. In Proceedings of the 28th Symposium on Chemical Information and Computer Sciences, 2005; Vol. 117, p 17.
21. Goto, J.; Kataoka, R.; Hirayama, N. In Proceedings of the 28th Symposium on Chemical Information and Computer Sciences, 2005; Vol. 123, p 51.